In this interactive roundtable, those responsible for greenlighting or killing the deal will share exclusive insights on the importance of IP in deal-making for the life sciences, the factors that influence deal evaluations, and effective communication strategies during negotiations. Topics of discussion will include:

• Working with the company’s bottom line: which IP due diligence red flags are deal-breakers, and which are salvageable from the business perspective?
• When is a license the better option over a merger or acquisition
• What considerations lead to an M&A vs. a license and/or collaboration?
• What questions outside counsel can ask towards developing an IP opinion that is tailored to the company’s goals and vision
• Exploring the value equation: unraveling the methodologies and considerations for valuing intellectual property assets
• What type of valuation consultations or assessments are the most helpful
• The key challenges and opportunities in deal-making from the business perspective specific to the IP due diligence process